CFON-026

CFON-026 is a preclinical-stage, non-covalent (reversible) small molecule inhibitor of Bruton's tyrosine kinase (BTK), developed by Crossfire Oncology. It is specifically designed to address resistance mechanisms associated with first- and second-generation covalent BTK inhibitors, such as the C481S mutation. By binding non-covalently, CFON-026 maintains potency against both wild-type BTK and common mutant variants that render covalent inhibitors ineffective. The drug is primarily being developed for the treatment of chronic lymphocytic leukemia (CLL) and other B-cell malignancies in patient populations that have progressed on or are resistant to existing BTK therapies. Crossfire Oncology plans to initiate clinical trials for CFON-026 in the second half of 2025.

Other names

CFON-026CFON026CFON 026